The following valve and structural heart repairs are commercially available. For information on investigational structural heart procedures, please see our research page.
Transcatheter aortic valve replacement (TAVR) is valve replacement without open-heart surgery. It is also called catheter-based or percutaneous aortic valve replacement. TAVR is for patients with aortic valve stenosis who are unable to withstand open heart surgery. The procedure includes placement of a balloon-expandable heart valve into the body with a tube-based delivery system (catheter).
Though TAVR was only recently approved by the FDA for certain patients, our center already has over four years of experience. We were the only hospital in Utah to participate in the procedure’s research and development. We were also the first in Utah approved to perform the procedure commercially.
The MitraClip device is now FDA approved for patients with worsening mitral valve regurgitation whose surgical risk is too high.
MitraClip is the first transcatheter mitral valve repair therapy available in the United States. The device is placed via a catheter from the femoral vein and does not require a chest incision, use of a heart-lung machine, or stopping of the heart.
Our center participated in the clinical trials that evaluated this device, and we continue to evaluate its use in other types of patients with mitral regurgitation.
Some patients with a hole between the two upper chambers of the heart (ASD, PFO) have clinical symptoms that warrant closure of the hole. Our program uses a procedure where a catheter guides a flexible closure device through a blood vessel into your heart. The flexible device is positioned inside the defect and expanded to close off the opening.
A ventricular septal defect (VSD) is a hole in the wall between the lower heart chambers – the right and left ventricles. VSDs may be present since birth or may develop as a complication of a heart attack. VSDs are associated with abnormal blood flow, and if larger, may be associated with shortness of breath. Larger VSDs may also lead to a dangerous and potentially fatal elevation of blood pressure in the lungs known as pulmonary hypertension.
Valve replacement surgery is common, safe, and effective in the United States. However, on rare occasion the new surgically placed valve may separate from the heart tissue where it is sewn in place. This separation results in a "paravalvular" gap between the surgically placed valve and the patient's own tissue. Blood flow through this defect may cause shortness of breath and blood cell destruction or anemia. These defects may be treated surgically or with catheter-based devices.
Hypertrophic cardiomyopathy is an inherited condition where the septum, which separates the right and left ventricles, becomes thick and obstructs blood flow out of the heart. The small area of the septum that obstructs blood flow may be restored to normal thickness with either a catheter-based procedure called septal ablation or heart surgery.